Company has more advertising in various media in order to publicize and promote the content, resulting in a decrease in net profit ratio (ROS) from 16.24% in 2017 to 16.00% in 2018. The total expense to
consolidated operating revenue of THB 188 million in Q4/2021 and THB 620 million in 2021, decreased by 9% from Q4/2020 and 19% from 2020, respectively. • The decrease was mainly from the decline in operating
) (3.62) (57.77) (3.65) SHARE OF PROFIT (LOSS) OF INVESTMENT IN JOINT VENTURES (0.66) (2.11) (7.84) 8.17 INCOME (LOSS) BEFORE TAX (62.94) 120.57 (66.41) 656.94 INCOME TAX INCOME (EXPENSE) 0.29 (7.05) 1.03
performance of the Group Unit: Million Baht 3Q17 3Q16 Increase (decrease) Variance (%) Total revenues 1,850 1,362 488 36% Net profit 54 95 (41) (43%) The Group has total revenues of Baht 1,850 million for 3Q17
million). In addition, the decrease in Sales was due to product mix (Table 5) and an adverse effect of unrealized consignment sales (Table 3, unrealized revenue amounted to Bt115 million in 2018). Cost of
revenue from sales and services amounted to Baht 7,815 million, decreased by Baht 334 million or 4% QoQ. This result from the decrease in sale volume and selling price while increase in production cost both
(LOSS) BEFORE TAX (117.62) (16.23) 109.89 (24.43) (7.73) (40.66) INCOME TAX INCOME (EXPENSE) 1.97 (1.10) - - 1.97 (1.10) NET GAIN (LOSS) FOR THE YEARS (115.65) (17.33) 109.89 (24.43) (5.76) (41.76) Unit
consolidated financial statements decreased by Baht 70.97 million or 2.46% compared with last year. A decrease mainly caused by trade accounts receivable of Baht 54.17 million. Decrease in cash and cash
for sales staff, traveling and vehicle expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and
expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of the Company’s